Profile - To The Moon

pinsheng

Posts · 2Posts · 2
Following · 0Following · 0
Followers · 0Followers · 0

- pinshengpinsheng
  ·2021-07-12
  Good
  New Alzheimer’s drug clouds outlook for Medicare premiums next year
  CHICAGO (Reuters) - The decision by U.S. drug regulators last month to approve a controversial treat
  New Alzheimer’s drug clouds outlook for Medicare premiums next year
  207 Comment
  Like
  Share
  Report
- pinshengpinsheng
  ·2021-06-22
  Nice
  Target unveils sustainability goals, pledging to keep its products out of landfills, create net-zero emissions by 2040
  KEY POINTS Target plans to make 100% of its private label products environmentally sustainable by d
  Target unveils sustainability goals, pledging to keep its products out of landfills, create net-zero emissions by 2040
  167 Comment
  Like
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3581941806993386","uuid":"3581941806993386","gmtCreate":1618847907955,"gmtModify":1624371600957,"name":"pinsheng","pinyin":"pinsheng","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/09a090b4773200903639b7c50baefa4a","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":4,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":146538366,"gmtCreate":1626089413055,"gmtModify":1703753093771,"author":{"id":"3581941806993386","authorId":"3581941806993386","name":"pinsheng","avatar":"https://static.tigerbbs.com/09a090b4773200903639b7c50baefa4a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581941806993386","authorIdStr":"3581941806993386"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/146538366","repostId":"2150538212","repostType":4,"repost":{"id":"2150538212","pubTimestamp":1626086940,"share":"https://ttm.financial/m/news/2150538212?lang=&edition=fundamental","pubTime":"2021-07-12 18:49","market":"us","language":"en","title":"New Alzheimer’s drug clouds outlook for Medicare premiums next year","url":"https://stock-news.laohu8.com/highlight/detail?id=2150538212","media":"StreetInsider","summary":"CHICAGO (Reuters) - The decision by U.S. drug regulators last month to approve a controversial treat","content":"<p>CHICAGO (Reuters) - The decision by U.S. drug regulators last month to approve a controversial treatment for Alzheimer’s disease could fuel an unusually large increase in Medicare premiums next year, but the outlook is clouded by a number of factors that will play out later this year.</p>\n<p>Biogen Inc's drug Aduhelm could create hope for millions of older Americans afflicted with Alzheimer’s - if it is effective in combating the disease. But the U.S. Food and Drug Administration (FDA) approved the drug despite objections from its own scientific advisory panel, which voted nearly unanimously that clinical trials did not demonstrate its effectiveness.</p>\n<p>Medicare typically covers FDA-approved drugs - but this <a href=\"https://laohu8.com/S/AONE\">one</a> comes with an eye-popping price tag set by its maker - $56,000 per patient annually. That figure does not include other associated care that could add tens of thousands of dollars of additional costs.</p>\n<p>Aduhelm will be administered by healthcare providers, and thus will be covered under Part B, rather than the Part D prescription drug program. And the impact on Part B finances could be huge. The premium paid by enrollees - which covers 25% of program costs - could rise sharply. So could the remainder of Part B costs, which are covered by all taxpayers.</p>\n<p>Predicting actual costs is speculative at this point due to uncertainty about the number of patients Medicare decides should have access to Aduhelm. But even a conservative estimate of $29 billion annually, from the Kaiser Family Foundation https://bit.ly/3jUrSpM, would nearly double Part B spending on drugs, which totaled $37 billion in 2019. (https://bit.ly/3jUrSpM)</p>\n<p>Medicare’s trustees will need to take into account the program’s likely spending on Aduhelm in 2022 as it sets the Part B premium, which typically is announced in November. And the new drug likely will have other impacts on the costs experienced by Medicare beneficiaries.</p>\n<p>Many enrollees in traditional Medicare also have supplemental Medigap policies that cover their coinsurance costs. Premiums for those policies could rise as insurers anticipate higher outlays associated with Aduhelm. And 10% of traditional Medicare enrollees do not have supplemental coverage, so they would be subject to the program’s 20% cost-sharing requirement for Aduhelm - roughly $11,500 per year.</p>\n<p>Out-of-pocket costs also would be an issue for enrollees in Medicare Advantage, the privately offered managed care alternative to the traditional program. Most Advantage enrollees are in plans that charge 20% coinsurance for Part B drugs provided in-network, mirroring the traditional program, according to Kaiser - the co-insurance rates can be much higher out of network.</p>\n<p>Medicare typically covers FDA-approved drugs, but it can conduct its own reviews in order to decide which types of patients should be covered. In the case of Aduhelm, Medicare could limit use to patients in the early stages of Alzheimer's. Just last week, the FDA narrowed its own recommendation for prescription of the drug, saying it should be used only with patients who have mild cognitive impairment or early dementia.</p>\n<p>Congress also could step in with legislation that mitigates any impact on Medicare enrollees. More broadly, the unusual FDA approval process and high cost for this drug could add fuel to the debate among legislators about broader drug-pricing reform.</p>\n<p>“This gives credence to the argument that the pharmaceutical industry cannot be relied on to deliver value to patients,” said Rachel Sachs, a professor of law at Washington University in St. Louis who wrote about the Aduhelm controversy https://bit.ly/3hrAzX7 recently for the journal Health Affairs. (https://bit.ly/3hrAzX7)</p>\n<p>OTHER PRESSURES</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> other factors could also put upward pressure on the Part B premium next year.</p>\n<p>Medicare increased the Part B premium this year by just $3.90, to $148.50 per month. But the increase actually was on track to be larger - Congress stepped in to cap it at 25% of whatever it would have been if Medicare had followed the usual formula, as part of a COVID-19 relief bill. That could set the stage for a larger “catch-up” increase this year.</p>\n<p>Healthcare utilization is another wild card. Despite the big surge in healthcare utilization last year associated with COVID-19, overall consumption of healthcare services fell dramatically during the lockdown last year. A key question is how this will impact utilization of services by Medicare enrollees next year. Utilization could be higher than normal as the pandemic recedes, putting further pressure on the Part B premium.</p>\n<p>THE COLA FACTOR</p>\n<p>The Aduhelm drama will play out against the backdrop of another pocketbook issue for seniors next year - the Social Security cost-of-living adjustment (COLA).</p>\n<p>The recent surge in inflation has some forecasters predicting a very hefty COLA next year. The widely watched Consumer Price Index for All Urban Consumers (CPI-U) jumped 5% in May from a year earlier - the biggest gain since August 2008, when it rose 5.3%. The final COLA number will be decided by monthly data during the third quarter for the Consumer Price Index for Urban Wage Earners and Clerical Workers (CPI-W).</p>\n<p>But for seniors who are enrolled in both Social Security and Medicare, the key figure is the net COLA after the Medicare Part B premium is deducted. Typically, some portion of the COLA is gobbled up by higher Part B premium costs. (The dollar amount of the Part B increase is deducted from the dollar amount of the COLA.)</p>\n<p>Put it all together, and it could be a roller coaster ride this fall for seniors monitoring these pocketbook issues.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Alzheimer’s drug clouds outlook for Medicare premiums next year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Alzheimer’s drug clouds outlook for Medicare premiums next year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-12 18:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18664195><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CHICAGO (Reuters) - The decision by U.S. drug regulators last month to approve a controversial treatment for Alzheimer’s disease could fuel an unusually large increase in Medicare premiums next year, ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18664195\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18664195","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2150538212","content_text":"CHICAGO (Reuters) - The decision by U.S. drug regulators last month to approve a controversial treatment for Alzheimer’s disease could fuel an unusually large increase in Medicare premiums next year, but the outlook is clouded by a number of factors that will play out later this year.\nBiogen Inc's drug Aduhelm could create hope for millions of older Americans afflicted with Alzheimer’s - if it is effective in combating the disease. But the U.S. Food and Drug Administration (FDA) approved the drug despite objections from its own scientific advisory panel, which voted nearly unanimously that clinical trials did not demonstrate its effectiveness.\nMedicare typically covers FDA-approved drugs - but this one comes with an eye-popping price tag set by its maker - $56,000 per patient annually. That figure does not include other associated care that could add tens of thousands of dollars of additional costs.\nAduhelm will be administered by healthcare providers, and thus will be covered under Part B, rather than the Part D prescription drug program. And the impact on Part B finances could be huge. The premium paid by enrollees - which covers 25% of program costs - could rise sharply. So could the remainder of Part B costs, which are covered by all taxpayers.\nPredicting actual costs is speculative at this point due to uncertainty about the number of patients Medicare decides should have access to Aduhelm. But even a conservative estimate of $29 billion annually, from the Kaiser Family Foundation https://bit.ly/3jUrSpM, would nearly double Part B spending on drugs, which totaled $37 billion in 2019. (https://bit.ly/3jUrSpM)\nMedicare’s trustees will need to take into account the program’s likely spending on Aduhelm in 2022 as it sets the Part B premium, which typically is announced in November. And the new drug likely will have other impacts on the costs experienced by Medicare beneficiaries.\nMany enrollees in traditional Medicare also have supplemental Medigap policies that cover their coinsurance costs. Premiums for those policies could rise as insurers anticipate higher outlays associated with Aduhelm. And 10% of traditional Medicare enrollees do not have supplemental coverage, so they would be subject to the program’s 20% cost-sharing requirement for Aduhelm - roughly $11,500 per year.\nOut-of-pocket costs also would be an issue for enrollees in Medicare Advantage, the privately offered managed care alternative to the traditional program. Most Advantage enrollees are in plans that charge 20% coinsurance for Part B drugs provided in-network, mirroring the traditional program, according to Kaiser - the co-insurance rates can be much higher out of network.\nMedicare typically covers FDA-approved drugs, but it can conduct its own reviews in order to decide which types of patients should be covered. In the case of Aduhelm, Medicare could limit use to patients in the early stages of Alzheimer's. Just last week, the FDA narrowed its own recommendation for prescription of the drug, saying it should be used only with patients who have mild cognitive impairment or early dementia.\nCongress also could step in with legislation that mitigates any impact on Medicare enrollees. More broadly, the unusual FDA approval process and high cost for this drug could add fuel to the debate among legislators about broader drug-pricing reform.\n“This gives credence to the argument that the pharmaceutical industry cannot be relied on to deliver value to patients,” said Rachel Sachs, a professor of law at Washington University in St. Louis who wrote about the Aduhelm controversy https://bit.ly/3hrAzX7 recently for the journal Health Affairs. (https://bit.ly/3hrAzX7)\nOTHER PRESSURES\nTwo other factors could also put upward pressure on the Part B premium next year.\nMedicare increased the Part B premium this year by just $3.90, to $148.50 per month. But the increase actually was on track to be larger - Congress stepped in to cap it at 25% of whatever it would have been if Medicare had followed the usual formula, as part of a COVID-19 relief bill. That could set the stage for a larger “catch-up” increase this year.\nHealthcare utilization is another wild card. Despite the big surge in healthcare utilization last year associated with COVID-19, overall consumption of healthcare services fell dramatically during the lockdown last year. A key question is how this will impact utilization of services by Medicare enrollees next year. Utilization could be higher than normal as the pandemic recedes, putting further pressure on the Part B premium.\nTHE COLA FACTOR\nThe Aduhelm drama will play out against the backdrop of another pocketbook issue for seniors next year - the Social Security cost-of-living adjustment (COLA).\nThe recent surge in inflation has some forecasters predicting a very hefty COLA next year. The widely watched Consumer Price Index for All Urban Consumers (CPI-U) jumped 5% in May from a year earlier - the biggest gain since August 2008, when it rose 5.3%. The final COLA number will be decided by monthly data during the third quarter for the Consumer Price Index for Urban Wage Earners and Clerical Workers (CPI-W).\nBut for seniors who are enrolled in both Social Security and Medicare, the key figure is the net COLA after the Medicare Part B premium is deducted. Typically, some portion of the COLA is gobbled up by higher Part B premium costs. (The dollar amount of the Part B increase is deducted from the dollar amount of the COLA.)\nPut it all together, and it could be a roller coaster ride this fall for seniors monitoring these pocketbook issues.","news_type":1},"isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129194706,"gmtCreate":1624363833005,"gmtModify":1703834413686,"author":{"id":"3581941806993386","authorId":"3581941806993386","name":"pinsheng","avatar":"https://static.tigerbbs.com/09a090b4773200903639b7c50baefa4a","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581941806993386","authorIdStr":"3581941806993386"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129194706","repostId":"1119651585","repostType":4,"repost":{"id":"1119651585","pubTimestamp":1624361869,"share":"https://ttm.financial/m/news/1119651585?lang=&edition=fundamental","pubTime":"2021-06-22 19:37","market":"us","language":"en","title":"Target unveils sustainability goals, pledging to keep its products out of landfills, create net-zero emissions by 2040","url":"https://stock-news.laohu8.com/highlight/detail?id=1119651585","media":"cnbc","summary":"KEY POINTS\n\nTarget plans to make 100% of its private label products environmentally sustainable by d","content":"<div>\n<p>KEY POINTS\n\nTarget plans to make 100% of its private label products environmentally sustainable by designing items that are more durable, and eliminate waste and encourage reuse by 2040.\nThe retailer ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/22/target-sets-sustainability-goals-net-zero-emissions-by-2040.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Target unveils sustainability goals, pledging to keep its products out of landfills, create net-zero emissions by 2040</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTarget unveils sustainability goals, pledging to keep its products out of landfills, create net-zero emissions by 2040\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 19:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/22/target-sets-sustainability-goals-net-zero-emissions-by-2040.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nTarget plans to make 100% of its private label products environmentally sustainable by designing items that are more durable, and eliminate waste and encourage reuse by 2040.\nThe retailer ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/22/target-sets-sustainability-goals-net-zero-emissions-by-2040.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TGT":"塔吉特"},"source_url":"https://www.cnbc.com/2021/06/22/target-sets-sustainability-goals-net-zero-emissions-by-2040.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1119651585","content_text":"KEY POINTS\n\nTarget plans to make 100% of its private label products environmentally sustainable by designing items that are more durable, and eliminate waste and encourage reuse by 2040.\nThe retailer also plans to have 100% of the plastic packaging for its brands recyclable, compostable or reusable by 2025.\nTarget said it is responding to growing consumer demand for more sustainable products and practices from companies.\n\nTargetis known for its exclusive merchandise, with private label brands for everything from arts and craft supplies to apparel. Now, the retailer is pledging to make all those products more environmentally sustainable.\nIt said Tuesday it will design items that are more durable and will eliminate waste and encourage reuse by 2040.\nWithin that time frame, Target is planning to become a net-zero enterprise, which means it will create zero waste for landfills at its U.S. operations and have net-zero emissions across its operations and supply chain.\nWhile these changes may not be apparent to consumers immediately, the retailer’s efforts are underway. Target said it has already launched a few products and initiatives with sustainability in mind. For example, its Universal Thread clothing uses sustainably sourced cotton and recycled polyester and its line of cleaning products, Everspring, uses 100% recyclable bottles and sprayers, compostable multisurface wipes and 100% recycled paper.\n“These standards are being worked on as we speak. You’ll see them throughout today and in the future. And then, as we launch new brands, that will be more embedded in what that brand launch looks like. So more to come,” said Amanda Nusz, the retailer’s senior vice president of corporate responsibility.\nAs it works toward this goal, Target has other benchmarks to reach even sooner. By 2025, all of its brands will use plastic packaging that is either recyclable, compostable or reusable.\nBy 2030, its goal is to be the market leader for creating and curating inclusive, sustainable brands and experiences, the company said.\nStarting this fall, the company will address single-use plastic bags as part of its Beyond the Bag initiative, which is looking to design retail bags that are less harmful to the environment.\nTarget said it is responding to growing consumer demand for more sustainable products and practices from companies.\nSeventy-two percent of U.S. consumers said sustainability is somewhat important or important when making purchase decisions, according to the results from the EY Future Consumer Index. The survey gathered information from 1,001 U.S. respondents and more than 14,000 global respondents in May.\nConsumers are so committed to sustainability that 30% said they are spending more on products that are sustainable and better for the environment and 31% said they plan to increase purchasing sustainable products in the next 12 months.\n“We spent over a year gathering information and listening,” Nusz said. “It’s a new era of sustainability for our company. Although it’s not new work, we are aiming to co-create an equitable and regenerative future with our guests, our partners and community.”\nThe goals Target announced Tuesday build on its earlier efforts. For example, Target signed on to theNew Plastics Economy Global Commitmentin 2018 to commit to eliminating plastic waste by making it reusable, recyclable or compostable. The company also has begun reducing its emissions and sourcing more of its power from renewable sources.\nOther retailers are responding to consumer demand for products that are less harmful for the environment.Walmartlaunched apartnership with ThredUp, a secondhand seller of apparel, shoes and accessories, to offer preowned items for women and children on Walmart’s website. ThredUp also has partnerships withGapandMacy’s.\nAdidashas set a goal to makenine of 10 products sustainable by 2025andLululemonpiloteda resale programthat allows customers to buy and sell used items. This month, it will expand the effort to its website.Levi’slaunched a campaign encouraging customers towear their jeans longerand avoid disposing of them.\n“As a company and a member of the global community, it’s imperative for both the health of our business and of our planet that we embrace new ways to move forward,” Chairman and CEO Brian Cornell said in a statement. “We know sustainability is tied to business resiliency and growth, and that our size and scale can drive change that is good for all.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}